Dr. Qian Jiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients

Dr. Qian Jiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients

From June 8th-11th, 2023, the 28th European Hematology Association (EHA) conference was held in Frankfurt, Germany. At the EHA meeting, Professor Jiang Qian's team from Peking University People's Hospital reported on the results of a study on reducing treatment doses for Chronic Myeloid Leukemia (CML) patients after achieving major molecular remission (abstract S158). During the conference, the "Tumor Watch" publication interviewed Dr. Qian Jiang, who elaborated on the current status of CML treatment, future prospects, and the initial intent and primary outcomes of the dosage reduction study.
Dr. Heather-Marie Schmidt: WHO Long-Acting PrEP Guidelines and Priority Actions to End HIV Epidemic in Asia  

Dr. Heather-Marie Schmidt: WHO Long-Acting PrEP Guidelines and Priority Actions to End HIV Epidemic in Asia  

Heather-Marie Schmidt BMedSc (Hon), MPH, PhD Dr. Schmidt serves as the Regional Advisor on HIV Testing, Prevention, and Key Populations for the Joint United Nations Programme on HIV/AIDS (UNAIDS) Asia-Pacific Regional Office and the World Health Organization (WHO) Global HIV, Hepatitis, and Sexually Transmitted Infections Program. She is dedicated to developing global guidelines for PrEP (Pre-Exposure Prophylaxis) and PEP (Post-Exposure Prophylaxis) and providing technical assistance to countries, organizations, and communities in the Asia-Pacific region to support the implementation and promotion of PrEP.
Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

Infectious Disease/HIV Specialist and Medical Professor at Monash University Alfred Hospital, Australia. Member of the Australian Antiretroviral Guidelines Committee and the International Antiviral Society-USA (IAS-USA) Antiretroviral Guidelines Panel. Leading and participating in the development of new antiretroviral drugs and the prevention and management of opportunistic infections, with a primary research focus on complications related to aging in HIV-infected individuals and their pathogenesis, prevention, and management.